meloxicam (Rx)

Brand and Other Names:Mobic, Vivlodex, more...Anjeso, Qmiiz
  • Print

Dosing & Uses


Dosage Forms & Strengths

tablet (Mobic)

  • 7.5mg
  • 15mg

tablet, oral distintegrating (Qmiiz)

  • 7.5mg
  • 15mg

capsule (Vivlodex)

  • 5mg
  • 10mg

injection, IV aqueous dispersion (Anjeso)

  • 30mg/mL single-dose vial


Indicated to relieve signs and symptoms of osteoarthritis

Mobic or Qmiiz: 7.5-15 mg PO qDay; not to exceed 15 mg/day

Vivlodex: Start with 5 mg PO qDay; if needed, may increase to 10 mg/day

Use the lowest effective dose for shortest duration consistent with individual patient treatment goals

Rheumatoid Arthritis

Indicated to relieve signs and symptoms of rheumatoid arthritis

Mobic or Qmiiz: 7.5-15 mg PO qDay; not to exceed 15 mg/day

Moderate-to-Severe Pain

Indicated for management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics

Anjeso: 30 mg IV qDay

Dosage Modifications

Hepatic impairment

  • Mild-to-moderate: No dosage adjustment required
  • Severe: Not studied

Renal impairment

  • Mild-to-moderate: No dosage adjustment required
  • Severe
    • Anjeso: : Not recommended; contraindicated in patients with moderate-to-severe renal insufficiency who are at risk for renal failure due to volume depletion
    • Mobic or Qmiiz: Not recommended
  • Hemodialysis
    • Mobic or Qmiiz: Not to exceed 7.5 mg/day
    • Vivlodex: Not to exceed 5 mg/day

Dosing Considerations

Vivlodex capsules and Qmizz ODT are not interchangeable with other formulations of oral meloxicam even if the mg strength is the same

Anjeso alone is not recommended for situations when rapid onset of analgesia required owing to the drug’s delayed onset of analgesia (mean onset 2-3 hr)

Dosage Forms & Strengths

tablet (Mobic)

  • 7.5mg
  • 15mg

tablet, oral distintegrating (Qmiiz)

  • 7.5mg
  • 15mg

Juvenile Idiopathic Arthritis

Indicated for relief of signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients who weigh ≥60 kg

60 kg or greater

  • Mobic tablet: 0.125 mg/kg PO qDay; not to exceed 7.5 mg/day  
  • Qmiiz ODT: 7.5 mg PO qDay


Interaction Checker

and meloxicam

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 
            Due to system maintenance, the drug interactions feature you are attempting to access is temporarily unavailable. Please try again later.

            Adverse Effects


            Indigestion (3.8-9.5%)

            Upper respiratory infection (≤8.3%)

            Headache (2.4-8.3%)

            Diarrhea (1.9-7.8%)

            Nausea (2.4-7.2%)

            Abdominal pain (1.9-4.7%)

            Edema (0.6-4.5%)

            Anemia (≤4.1%)

            Dizziness (1.1-3.8%)

            Constipation (0.8-2.6%)

            Angina (<2%)

            Congestive heart failure (<2%)

            Decreased platelet aggregation, purpuric disorder (<2%)

            Gastrointestinal (GI) hemorrhage (<2%)

            GI perforation, GI ulcer (<2%)

            Hepatitis (<2%)

            Hypertension (<2%)

            Inflammatory disorder of digestive tract (<2%)

            Myocardial infarction (<2%)

            Vomiting (<3%)


            • Constipation (7.6%)
            • GGT increased (2.8%)
            • Anemia (2.4%)


            Anaphylactoid reaction



            Asthma, bronchospasm

            Cerebrovascular accident

            Erythema multiforme, erythroderma

            Immune hypersensitivity reaction

            Interstitial nephritis, renal failure

            Jaundice, liver failure

            Stevens-Johnson syndrome

            Tinnitus, hearing loss

            Toxic epidermal necrolysis



            Black Box Warnings

            Cardiovascular risk

            • Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke, which can be fatal
            • Risk may increase with duration of use
            • Patients with existing cardiovascular disease or risk factors for such disease may be at greater risk
            • NSAIDs are contraindicated for perioperative pain in setting of coronary artery bypass graft (CABG) surgery

            Gastrointestinal risk

            • NSAIDs increase risk of serious GI adverse events, including bleeding, ulceration, and gastric or intestinal perforation, which can be fatal
            • GI adverse events may occur at any time during use and without warning symptoms
            • Elderly patients are at greater risk for serious GI events


            Known hypersensitivity (eg, anaphylactic or serious skin reactions)

            History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs

            Perioperative pain management in the setting of coronary artery bypass graft (CABG) surgery

            Anjeso: Moderate-to-severe renal insufficiency in patients at risk for renal failure owing to volume depletion

            Qmiiz: Phenylketonuria


            Cardiovascular thrombotic events

            • Increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal
            • Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs
            • The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease; however, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events
            • Increased CV thrombotic risk has been observed most consistently at higher doses
            • Minimize potential risk by using lowest effective dose for the shortest duration possibleCABG
              • 2 large, controlled clinical trials of a COX-2 selective NSAID for pain in the first 10-14 days following CABG surgery found an increased incidence of MI and stroke
              • NSAIDs are contraindicated in the setting of CABG
            • Post-MI
              • Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs post-MI were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment
              • Avoid in patients with recent MI unless benefits outweigh risk of recurrent CV thrombotic events; if used, monitor for cardiac ischemia

            GI effects

            • NSAIDs can cause serious GI adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal
            • Patients with a prior history of PUD and/or GI bleeding who used NSAIDs have >10-fold increased risk for developing a GI bleed compared with patients without these risk factors
            • Other risk factors include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or SSRIs; smoking; use of alcohol; advanced liver disease and /or coagulopathy; older age; and poor general health status

            Heart failure and edema

            • The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an ~2-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared with placebo-treated patients
            • Fluid retention and edema observed in some patients treated with NSAIDs
            • Meloxicam may blunt the CV effects of several therapeutic agents used to treat these medical conditions (eg, diuretics, ACE inhibitors, ARBs)

            Renal toxicity and hyperkalemia

            • Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury
            • NSAIDs are not recommended with moderate to severe renal insufficiency and are contraindicated in patients with moderate to severe renal insufficiency at risk for renal failure due to volume depletion
            • Increased serum potassium concentration, including hyperkalemia, reported with NSAIDs, even in some patients without renal impairment

            Asthma exacerbation

            • A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs
            • Contraindicated in aspirin-sensitive asthma owing to cross-reactivity
            • Caution in patients with asthma without known aspirin sensivitiy

            Drug reaction with eosinophilia and systemic symptoms (DRESS)

            • Drug Reaction reported in patients taking NSAIDs; some of these events have been fatal or life-threatening; DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling
            • Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis; sometimes symptoms of DRESS may resemble an acute viral infection
            • Eosinophilia is often present; because this disorder is variable in its presentation, other organ systems not noted here may be involved
            • Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident; if such signs or symptoms are present, discontinue therapy and evaluate the patient immediately

            Additional cautions

            • Hepatotoxicity: May increase ALT or AST
            • Hypertension: Can lead to new onset of hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events
            • Anaphylactic reactions reported in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma
            • Serious skin reactions reported, including exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, which can be fatal
            • Premature closure of fetal ductus arteriosus: Avoid NSAIDs in pregnant women starting at 30 weeks of gestation (third trimester)
            • Hematologic toxicity: Anemia reported; causes vary including blood loss, fluid retention, or effect on erythropoiesis
            • Masking of inflammation and fever: Reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections
            • Monitoring: Consider monitoring patients on long-term PO NSAID treatment with a CBC and a chemistry profile periodically to detect GI bleeding, hepatotoxicity, or renal injury
            • IV meloxicam not indicated for long-term treatment
            • Qmiiz ODT contains phenylalanine; contraindicated in patients with phenylketonuria

            Drug interaction overview

            • CYP2C9 inhibitors
              • Meloxicam is a CYP2C9 substrate
              • Coadministration with CYP2C9 inhibitors (eg, amiodarone, fluconazole) may increase meloxicam plasma levels owing to reduced metabolic clearance
              • Consider meloxicam dose reduction
            • Drugs that interfere with hemostasis
              • Monitor if coadministered with anticoagulants (eg, warfarin), antiplatelet agents (eg, aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding
              • Coadministration with analgesic doses of aspirin is not recommended owing to increased risk of bleeding
              • If coadministration with low-dose aspirin for cardiac prophylaxis, monitor closely for evidence of GI bleeding
            • ACE inhibitors, ARBs, or beta blockers
              • NSAIDs may diminish antihypertensive effect of ACE inhibitors, angiotensin receptor blockers (ARBs), or beta blockers
              • In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, coadministration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure; these effects are usually reversible
              • If coadministered, patients should be well hydrated; monitor for signs of worsening renal function
            • Diuretics
              • NSAIDs may reduce the natriuretic effect of loop and thiazide diuretics
              • This effect is attributed to the NSAID inhibition of renal prostaglandin synthesis
              • However, studies with furosemide and meloxicam have not demonstrated a reduced natriuretic effect
            • Lithium
              • NSAIDs elevate plasma lithium levels and reduce renal lithium clearance
              • Mean minimum lithium concentration increased 15%; renal clearance decreased by ~20%
              • Effect attributed to NSAID inhibition of renal prostaglandin synthesis
              • Monitor for lithium toxicity
            • Methotrexate
              • Coadministration of NSAIDs and methotrexate may increase risk for methotrexate toxicity (eg, neutropenia, thrombocytopenia, renal dysfunction)
            • Cyclosporine
              • Coadministration may increase nephrotoxicity
              • If coadministered, monitor for worsening renal function
            • NSAIDs or salicylates
              • Coadministration with other NSAIDs or salicylates increases risk of GI toxicity, with little or no increase in efficacy
              • Concomitant use no recommended
            • Pemetrexed
              • Coadministration may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity
              • CrCl 45-79 mL/min: Interrupt meloxicam dosing for at least 5 days before, the day of, and 2 days after pemetrexed administration
              • CrCl <45 mL/min: Concomitant administration of meloxicam with pemetrexed is not recommended

            Pregnancy & Lactation


            Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive

            Fetal toxicity

            • Avoid use of NSAIDs in pregnant women at about 30 weeks gestation and later; NSAIDs increase risk of premature closure of fetal ductus arteriosus at approximately this gestational age
            • Use of NSAIDs at about 20 weeks gestation or later in pregnancy may also cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment
            • These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation
            • Oligohydramnios is often, but not always, reversible with treatment discontinuation; complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation
            • In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required
            • If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit use to the lowest effective dose and shortest duration possible
            • Consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours; discontinue drug if oligohydramnios occurs and follow up according to clinical practice

            Animal studies

            • Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization
            • In animal studies, administration of prostaglandin synthesis inhibitors, such as meloxicam, resulted in increased pre- and post-implantation loss

            Clinical considerations

            • Human data are not available on the effects during labor or deliveryIn animal studies, NSAIDs inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth


            • Females
              • Based on the mechanism of action, prostaglandin-mediated NSAIDs may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women
            • Males
              • May compromise fertility in males of reproductive potential
              • Oral administration of meloxicam to male rats for 35 days resulted in decreased sperm count and motility and histopathological evidence of testicular degeneration at 0.3-times the MRHD based on BSA comparison
              • The clinical relevance of these findings is unknown


            Human data are not available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production

            Animal data

            • Present in milk of lactating rats at concentrations higher than those in plasma

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.



            Mechanism of Action

            Member of oxicam class; inhibits synthesis of prostaglandins in body tissues by inhibiting at least 2 cyclo-oxygenase (COX) isoenzymes, COX-1 and COX-2; COX-2 may be inhibited to a greater extent than COX-1 is


            Bioavailability: 89%

            Peak plasma time

            • Mobic tab: 6.57 hr
            • Vivlodex cap: 2 hr (fasting); 5 hr (fed)
            • Anjeso IV: 0.12 hr

            Peak plasma concentration

            • Mobic tab: 1221.9 ng/mL
            • Anjeso IV: 5642.9 ng/mL


            • Mobic tab: 53,988.8 ng⋅hr/mL
            • Anjeso IV: 107,508.7 ng⋅hr/mL


            Protein bound: 99.4%; primarily to albumin

            Vd: ~10 L


            Metabolized in liver by CYP2C9 (major) and CYP3A4 (minor)

            Metabolites (inactive): 5'-Carboxy meloxicam, 5'-hydroxymethyl meloxicam

            Enzymes inhibited: COX-1, COX-2


            Half-life: 15-20 hr (PO); 24 hr (IV)

            Plasma clearance: 7-9 mL/min

            Dialyzable: No

            Excretion: Equally excreted in urine and feces, mostly as metabolites


            Poor CYP2C9 metabolizers

            • Consider dose meloxicam reduction
            • Abnormally high plasma levels owing to reduced metabolic clearance may occur


            Oral Administration

            Tablet, capsule, or ODT: May take with or without meals

            Oral disintegrating tablet (ODT)

            • Leave ODT in original package until the time of administration
            • Use dry hands when handling ODT
            • Open carton and peel back foil on the blister; do not push the tablet through the foil as this could damage the tablet
            • Gently remove tablet from the blister and immediately place in mouth or onto tongue
            • Tablet will disintegrate quickly in saliva and can be easily swallowed with or without drinking liquid

            IV Administration

            Anjeso: IV bolus injected over 15 seconds

            Hydrate before administering to reduce risk of renal toxicity


            Capsule or tablet

            • Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF)
            • Store in original container and keep the bottle tightly closed to protect from moisture
            • Dispense in a tight container if package is subdivided

            Oral disintegrating tablet

            • Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)
            • Avoid high humidity and excessive heat above 40ºC (104ºF)


            • Store at 15-25ºC (59-77ºF); excursions permitted to 4-30ºC (40-86ºF)
            • Do not freeze
            • Protect from light
            • Latex-free


            Anjeso intravenous
            30 mg/mL vial
            meloxicam oral
            15 mg tablet
            meloxicam oral
            15 mg tablet
            meloxicam oral
            15 mg tablet
            meloxicam oral
            7.5 mg tablet
            meloxicam oral
            15 mg tablet
            meloxicam oral
            7.5 mg tablet
            meloxicam oral
            7.5 mg tablet
            meloxicam oral
            15 mg tablet
            meloxicam oral
            7.5 mg tablet
            meloxicam oral
            7.5 mg tablet
            meloxicam oral
            15 mg tablet
            meloxicam oral
            7.5 mg tablet
            meloxicam oral
            15 mg tablet

            Copyright © 2010 First DataBank, Inc.


            Patient Handout

            Patient Education
            meloxicam oral

            MELOXICAM - ORAL


            COMMON BRAND NAME(S): Mobic, Vivlodex

            WARNING: Nonsteroidal anti-inflammatory drugs (including meloxicam) may rarely increase the risk of a heart attack or stroke. This effect can happen at any time while taking this drug but is more likely if you take it for a long time. The risk may be greater in older adults or if you have heart disease or increased risk for heart disease (for example, due to smoking, family history of heart disease, or conditions such as high blood pressure or diabetes). Do not take this drug right before or after heart bypass surgery (CABG).Also, this drug may rarely cause serious (rarely fatal) bleeding from the stomach or intestines. This effect can occur without warning symptoms at any time while taking this drug. Older adults may be at higher risk for this effect. (See also Precautions and Drug Interactions sections.)Stop taking meloxicam and get medical help right away if you notice any of the following rare but serious side effects: stomach/abdominal pain that doesn't go away, bloody or black/tarry stools, vomit that looks like coffee grounds, chest/jaw/left arm pain, shortness of breath, unusual sweating, weakness on one side of the body, sudden vision changes, trouble speaking.Talk with your doctor or pharmacist about the risks and benefits of treatment with this medication.

            USES: Meloxicam is used to treat arthritis. It reduces pain, swelling, and stiffness of the joints. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID).If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.

            HOW TO USE: Read the Medication Guide provided by your pharmacist before you start taking meloxicam and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth as directed by your doctor, usually once daily. If you are taking the tablet or capsule form of this medication, drink a full glass of water (8 ounces/240 milliliters) with it unless your doctor tells you otherwise. Do not lie down for at least 10 minutes after taking the tablet or capsule form of this medication.If you are taking the liquid form of this medication, shake the bottle gently before each dose. Carefully measure the dose using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.If you are taking the disintegrating tablet, do not remove the tablet from the packaging until you are ready to take it. With dry hands, peel back the foil to carefully remove the tablet. Do not push the tablet through the foil because doing so can damage it. Place the tablet on your tongue right away and allow it to dissolve. After the tablet has melted, it can be swallowed with or without liquid.If stomach upset occurs while taking this medication, take it with food, milk, or an antacid. The dosage is based on your medical condition and response to treatment. The lowest effective dosage should always be used, and only for the prescribed length of time. Do not take more of this medication than prescribed because higher doses increase the chance of stomach ulcers/bleeding.Meloxicam may come in different forms (such as tablet, capsule, liquid, disintegrating tablet). Do not switch between different forms without consulting your doctor.It may take up to two weeks before you get the full benefit of this drug. Use this medication regularly to get the most benefit from it. Remember to use it at the same time each day.Tell your doctor if your condition worsens.

            SIDE EFFECTS: See also Warning section.Stomach upset, nausea, dizziness, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.This medication may raise your blood pressure. Check your blood pressure regularly and tell your doctor if the results are high.Tell your doctor right away if you have any serious side effects, including: headache that is severe or doesn't go away, easy bruising/bleeding, mental/mood changes, signs of kidney problems (such as change in the amount of urine), unexplained stiff neck, symptoms of heart failure (such as swelling ankles/feet, unusual tiredness, unusual/sudden weight gain).This drug may rarely cause serious (possibly fatal) liver disease. Get medical help right away if you have any symptoms of liver damage, including: nausea/vomiting that doesn't stop, loss of appetite, dark urine, stomach/abdominal pain, yellowing eyes/skin.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: fever, swollen lymph nodes, rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Before taking meloxicam, tell your doctor or pharmacist if you are allergic to it; or to aspirin or other NSAIDs (such as ibuprofen, naproxen, celecoxib); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: asthma (including a history of worsening breathing after taking aspirin or other NSAIDs), liver disease, stomach/intestine/esophagus problems (such as bleeding, ulcers, recurring heartburn), heart disease (such as history of heart attack), high blood pressure, stroke, blood disorders (such as anemia, bleeding/clotting problems), growths in the nose (nasal polyps).Kidney problems can sometimes occur with the use of NSAID medications, including meloxicam. Problems are more likely to occur if you are dehydrated, have heart failure or kidney disease, are an older adult, or if you take certain medications (see also Drug Interactions section). Drink plenty of fluids as directed by your doctor to prevent dehydration and tell your doctor right away if you have a change in the amount of urine.This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Talk to your doctor if you are using marijuana (cannabis).This medication may cause stomach bleeding. Daily use of alcohol and tobacco, especially when combined with this medication, may increase your risk for stomach bleeding. Limit alcohol and smoking. Consult your doctor or pharmacist for more information.The disintegrating tablet form of meloxicam may contain aspartame. If you have phenylketonuria (PKU) or any other condition that requires you to limit/avoid aspartame (or phenylalanine) in your diet, ask your doctor or pharmacist about using this medication safely.This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be at greater risk for stomach/intestinal bleeding, kidney problems, heart attack, and stroke while using this drug.Before using this medication, women of childbearing age should talk with their doctor(s) about the benefits and risks. Tell your doctor if you are pregnant or if you plan to become pregnant. This medication may harm an unborn baby and cause problems with normal labor/delivery. It is not recommended for use in pregnancy from 20 weeks until delivery. If your doctor decides that you need to use this medication between 20 and 30 weeks of pregnancy, you should use the lowest effective dose for the shortest possible time. You should not use this medication after 30 weeks of pregnancy.It is unknown if this medication passes into breast milk. However, similar drugs pass into breast milk and are unlikely to harm a nursing infant. Consult your doctor before breast-feeding.

            DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: aliskiren, ACE inhibitors (such as captopril, lisinopril), angiotensin II receptor blockers (such as losartan, valsartan), cidofovir, lithium, methotrexate (high-dose treatment), "water pills" (diuretics such as furosemide).This medication may increase the risk of bleeding when taken with other drugs that also may cause bleeding. Examples include anti-platelet drugs such as clopidogrel, "blood thinners" such as dabigatran/enoxaparin/warfarin, among others.If you are using the liquid form of meloxicam, tell your doctor if you are also using sodium polystyrene sulfonate.Check all prescription and nonprescription medicine labels carefully since many medications contain pain relievers/fever reducers (aspirin, NSAIDs such as celecoxib, ibuprofen, or ketorolac). These drugs are similar to meloxicam and may increase your risk of side effects if taken together. However, if your doctor has directed you to take low-dose aspirin to prevent heart attack or stroke (usually 81-162 milligrams a day), you should continue taking the aspirin unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: slow/shallow breathing, extreme drowsiness, severe stomach pain, vomit that looks like coffee grounds.

            NOTES: Do not share this medication with others.Lab and/or medical tests (such as blood counts, blood pressure, kidney/liver function) may be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.Non-drug treatment for arthritis that is approved by your doctor (such as weight loss if needed, strengthening and conditioning exercises) may help improve your flexibility, range of motion, and joint function. Consult your doctor for more information.

            MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

            STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

            Information last revised December 2022. Copyright(c) 2022 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.



            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.